Last reviewed · How we verify

Diffuse non-Hodgkin's lymphoma, large cell — Treatment Landscape & Competitive Intelligence

Diffuse non-Hodgkin's lymphoma, large cell (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diffuse non-Hodgkin's lymphoma, large cell, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Gliadel CARMUSTINE Avet Lifesciences Alkylating Drug Glutathione reductase, mitochondrial 1977-01-01
Doxorubicin Hydrochloride doxorubicin Pfizer Anthracycline Topoisomerase Inhibitor Aurora kinase A 1974-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer doxorubicin 72 kDa type IV collagenase 1974-01-01
Blenoxane BLEOMYCIN Bristol-Myers Squibb Cytoprotective Agent Aspartyl/asparaginyl beta-hydroxylase 1973-01-01
Oncovin vincristine Pfizer Inc. Vinca Alkaloid Canalicular multispecific organic anion transporter 1 1963-01-01
Oncovin Vincristine Sulfate Pfizer Inc. Vinca Alkaloid Canalicular multispecific organic anion transporter 1 1963-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Adriamycin Adriamycin Johann Wolfgang Goethe University Hospital Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Vincristin Vincristin Arbeitsgemeinschaft medikamentoese Tumortherapie Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. University of Colorado, Denver · 2 drugs in Diffuse non-Hodgkin's lymphoma, large cell
  2. Pfizer Inc. · 2 drugs in Diffuse non-Hodgkin's lymphoma, large cell
  3. Pfizer · 2 drugs in Diffuse non-Hodgkin's lymphoma, large cell
  4. Chipscreen Biosciences, Ltd. · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  5. Generic (originally Merck) · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  6. Generic (originally Schering) · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  7. Johann Wolfgang Goethe University Hospital · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  8. University Hospital Freiburg · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  9. Weill Medical College of Cornell University · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  10. Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  11. Wen Zhang · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell
  12. Avet Lifesciences · 1 drug in Diffuse non-Hodgkin's lymphoma, large cell

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diffuse non-Hodgkin's lymphoma, large cell:

Cite this brief

Drug Landscape (2026). Diffuse non-Hodgkin's lymphoma, large cell — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diffuse-non-hodgkin-s-lymphoma-large-cell. Accessed 2026-06-09.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing